论文部分内容阅读
继今年5月浙江工业大学牵头的“长三角绿色制药协同创新中心”通过教育部、财政部“2012年度国家协同创新中心”认定后,10月17日,该校再获批国家化工原料原料合成工程技术研究中心。中心先后研发了有毒有害物质绿色替代技术、不对称生物催化技术、化学与生物耦合技术等一批拥有自主知识产权的原料药生产关键和共性技术,并且被广泛应用于多个省市的200余家医药企业,创造了显著社会效益和经济效益。其中,中心研发的替代光气、氯化亚砜等有毒有害原料的绿色制药技术,从工艺源头上消除或大幅度减少了安全和环境隐患,并在国内十余家规模以上医药企业实现了产业化,2004年
Following the lead by the Zhejiang University of Technology in May this year, “Yangtze River Delta Green Pharmaceutical Collaborative Innovation Center” through the Ministry of Education, the Ministry of Finance “2012 National Collaborative Innovation Center ” after the confirmation, on October 17, the school re-approved countries Chemical raw materials synthesis Engineering Research Center. The center has developed a number of key and common technologies for the production of bulk pharmaceuticals with independent intellectual property rights, such as green alternative technologies for toxic and hazardous substances, asymmetric biocatalysis and chemical and biological coupling technologies, and are widely used in more than 200 provinces and municipalities Home pharmaceutical companies, has created significant social and economic benefits. Among them, the green pharmaceutical technology developed by the center to replace the poisonous and harmful raw materials such as phosgene and thionyl chloride eliminated or greatly reduced the safety and environmental risks from the source of the process, and realized the industrialization of more than 10 large-scale pharmaceutical enterprises in China 2004